A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

NCT04279405 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Lymphocytic Lymphoma
Lymphoplasmacytic Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: YY-20394

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.